Associations of Lipid Measures With Premature Myocardial Infarction: a Cross-sectional Study
Launched by YUE LI · Dec 2, 2022
Trial Information
Current as of January 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • According to the fourth Universal Definition of Myocardial Infarction (2018), the clinical diagnosis was acute myocardial infarction (AMI), including type 1, 2, 3, 4b and 4c.
- • Complete coronary angiography
- • Complete biochemical and blood lipid tests
- Exclusion Criteria:
- • Recurrent AMI
- • The onset of AMI exceeds 7 days
- • Continuous taking of lipid-lowering drugs ≥ 5 days
- • Patients with missing data
About Yue Li
Yue Li is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on precision medicine and a robust portfolio of clinical studies, Yue Li collaborates with leading healthcare institutions and research organizations to ensure the highest standards of scientific rigor and ethical integrity. The organization prioritizes patient safety and well-being, leveraging cutting-edge methodologies to facilitate the development of new treatments across various therapeutic areas. Yue Li's mission is to contribute to the evolution of healthcare by fostering breakthroughs that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harbin, Heilongjiang, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials